EMC Corp. (NYSE: EMC), whose storage solutions already help to alleviate this data glut, has been innovating and integrating new technologies in order to secure its position as the largest data storage provider in the world. Read More
Archive
Filter
[from the 7/7/2015 edition of Smart Tech 50 Weekly Movers]Although we do not advocate trading the stock market on a short term basis (which we define as a holding period of less than one year), sometimes our model is so accurate in predicting the near term direction of… Read More
[from the 7/7/2015 edition of Smart Tech 50 Weekly Movers]Although we do not advocate trading the stock market on a short term basis (which we define as a holding period of less than one year), sometimes our model is so accurate in predicting the near term direction of… Read More
Turmoil surrounding the Greek debt crisis has brought one of our favorite stocks back down to an attractive level, so we are once again adding it our Investments Portfolio. Read More
For the reasons described in the 6/29/2015 edition of Smart Tech 50 Weekly Movers, we are adding Meridian Biosciences (VIVO) to the Medical Profits portfolio with a buy limit price of $19 and a stop loss at $16. Read More
For the reasons described in the 6/29/2015 edition of Smart Tech 50 Weekly Movers, we are adding Meridian Biosciences (VIVO) to the Medical Profits portfolio with a buy limit price of $19 and a stop loss at $16. Read More
In this issue:In Depth: New EBIS Buy: Meridian Biosciences (VIVO)Portfolio Update: News on Repligen, Medivation, News Update: Are Migraines the Next Biotech Frontier?This week we are featuring two Big Picture charts as an interesting relationship is developing between the biotech sector and the bond market. The Nasdaq Biotech Index (NBI) delivered… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
As much as we loved the idea of making trading recommendations based on short term opportunities we saw in the tech sector, the feedback we got from our subscribers is that they would prefer a longer term, and more focused portfolio. For that reason, we are renaming our Equity Trades… Read More
All told, over 2.5 million Americans are candidates for exoskeletons currently available or already under development. With only about 250 sold to date – and sales accelerating each month – the potential is virtually limitless. Read More